<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781454</url>
  </required_header>
  <id_info>
    <org_study_id>MX-ALS-002</org_study_id>
    <nct_id>NCT02781454</nct_id>
  </id_info>
  <brief_title>Mexiletine in Sporadic Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>Mexiletine-2</acronym>
  <official_title>Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out whether the drug mexiletine will be
      effective in lowering motor neuron electrical activity in the brains and nerves in the arms
      of people with ALS. The investigators will also determine if there are any signs that the
      drug may slow down the progression of ALS and reduce muscle cramps and muscle twitching. This
      will be determined through transcranial magnetic stimulation (TMS) and threshold tracking
      nerve conduction studies (TTNCS). In this trial, the participants will be taking either
      300mg/day of mexiletine, 600mg/day of mexiletine, or placebo (non-active study drug).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily motor
      neurons, for which treatment designed to slow or arrest progression remains lacking.
      Mexiletine is a use-dependent sodium channel blocker that has been FDA-approved for decades
      for the treatment of cardiac arrhythmias and more recently to treat neuropathic pain in
      diabetic polyneuropathy. Mexiletine has been shown also to be protective of neurons following
      spinal cord, head injury, and cerebral ischemia, largely by blocking excitotoxicity. Based on
      previous studies, mexiletine appears to penetrate into the central nervous system at
      concentrations sufficient to confer significant protection. Recent unpublished studies in the
      laboratory of Dr. Robert Brown at the University of Massachusetts have also demonstrated that
      mexiletine ingestion in mice genetically engineered to express high levels of mutant
      cytosolic copper-zinc superoxide dismutase-1 (SOD1) transgene prolongs survival in these
      animals. As mexiletine already has FDA-approval as an anti-arrhythmic agent, much is known
      about the pharmacology and safety of this drug in non-ALS patients. We anticipate that by
      excluding subjects with a known history of cardiac disease and with the known neuroprotectant
      properties of this medication, mexiletine is a good choice for further study in an ALS
      clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Resting Motor Threshold</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 and from Week 4 to Week 8 reported</time_frame>
    <description>The resting motor threshold (RMT) assessed from single pulse transcranial magnetic stimulation (TMS) measurements made before treatment, after 4 weeks of treatment, and then again after a 4 week washout, was used as the primary pharmacodynamic marker of cortical hyperexcitability. RMT is the stimulus intensity required to produce and maintain a 0.2 mV peak-to-peak motor evoked potential of the abductor pollicis brevis muscle by TMS. A smaller RMT is thought to suggest greater neuronal excitability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on Short-interval Intracortical Inhibition</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>Short-interval intracortical inhibition (SICI) is a measure of neuronal excitability measured by dual pulse TMS with a conditioned (80% of RMT) and test pulses (120% of RMT) to generate a stable MEP amplitude of 0.2 mV, averaged over interstimulus intervals of 1-7 ms. It is thought to reflect refractory cortical axons and subsequent resynchronization of cortico-cortical and corticomotoneuronal volleys or activation of non-GABAergic cortical inhibitory circuits (initial phase) and synaptic neurotransmission through GABAA receptors (second phase). The value for SICI thought to be maximally sensitive for detecting in changes in ALS subjects compared to controls is is derived by measuring the motor evoked potential amplitude (MEP) at an interstimulus interval of 3 ms (ISI 3 ms) and normalizing to the MEP amplitude at 120% of the resting motor threshold (MEP 120% RMT). A reduction in SICI reflecting greater excitability would generate a larger ratio of MEP ISI 3 ms/MEP 120% RMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Motor Evoked Potential Amplitude</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>The motor evoked potential (MEP) amplitude is taken from single pulse transcranial magnetic stimulation (TMS) and reflects the density of corticomotoneuronal projections onto motor neurons and is affected by cortical hyperexcitability early in ALS where it is thought to be larger than age-matched controls and axonal degeneration later in the disease when it decreases in amplitude. The MEP is most reliable in assessing cortical motor neuronal preservation and excitability when normalized to the peak compound nerve action potential (CMAP) amplitude which reflects the integrity of peripheral motor nerve axons. It is also normalized here to 120% of the RMT to derive a ratio of MEP at 120% RMT/peak CMAP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Cortical Silent Period</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>The cortical silent period (CSP) is recorded with single pulse TMS as a duration from the onset of the MEP response to resumption of voluntary electromyography activity with the patient performing a voluntary contraction, set to 30% of maximal voluntary contraction. A shorter CSP compared to controls would reflect greater excitability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Strength Duration Time Constant</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>The strength duration time constant (SDTC) is used in threshold tracking nerve axonal excitability studies and is interpreted as a measure of axonal excitability that is dependent upon the biophysical properties of the axonal membrane at the node of Ranvier, especially persistent sodium current. It is derived from the relationship between stimulus duration and intensity. A higher SDTC would reflect greater excitability of motor nerve axons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Depolarizing Threshold Electrotonus (90-100 ms)</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>Depolarizing threshold electrotonus (90-100 ms) (TEd 90-100 ms) is used in threshold tracking nerve axonal excitability studies in which long-lasting subthreshold depolarizing currents are generated, measured at 90-100 ms following the stimulus. This measure is associated with a decrease in the membrane excitability threshold due to opening of potassium channels on the axonal membrane. Intrinsic changes in axonal excitability properties, such as thought to occur in ALS, could possibly alter this measure, presumably by decreasing TEd 90-100 ms more substantially than normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Hyperpolarizing Threshold Electrotonus (90-100 ms)</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>Hyperpolarizing threshold electrotonus (90-100 ms) (TEh 90-100 ms) is used in threshold tracking nerve axonal excitability studies in which long-lasting subthreshold hyperpolarizing currents are generated, measured at 90-100 ms following the stimulus. This measure is associated with an increase in the membrane excitability threshold due to closure of potassium channels causing increased resistance of the internodal axonal membrane. Intrinsic changes in axonal excitability properties, such as thought to occur in ALS, could possibly alter this measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Superexcitability</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>Superexcitability is a component of recovery cycle analysis assessing motor axonal excitability, employing threshold tracking nerve conduction study. It is a depolarizing afterpotential measured following a single supramaximal stimulus followed by a second smaller stimulus of variable intensity and reflects passive depolarization of the internodal axon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Subexcitability</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>Subexcitability is a component of recovery cycle analysis assessing motor axonal excitability, employing threshold tracking nerve conduction study. It is a late hyperpolarizing after potential measured following a single supramaximal stimulus followed by a second smaller stimulus of variable intensity and is related to the very slow turn-off of slow potassium channels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Frequency of Muscle Cramps</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; comparisons of treatments at Weeks 3-4 reported</time_frame>
    <description>Will be assessed using a daily muscle cramps diary tabulated weekly beginning at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Frequency of Fasciculations (Muscle Twitching)</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; comparisons of treatments at Weeks 3-4 reported</time_frame>
    <description>Will be assessed using a daily fasciculations diary tabulated as a percentage of days from weeks 3-4.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>The Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) is an instrument for evaluating the functional status of patients with ALS that includes functions related to speech, swallowing, salivation, fine motor control, gross motor function, and respiration. The score is the sum of 12 items (range 0 to 48) with higher scores reflecting better function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Slow Vital Capacity</measure>
    <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
    <description>Measure of decline in respiratory muscle strength</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Sporadic Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Mexiletine, 300 milligrams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mexiletine, 600 milligrams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, by mouth per day for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mexiletine</intervention_name>
    <arm_group_label>Mexiletine, 300 milligrams</arm_group_label>
    <arm_group_label>Mexiletine, 600 milligrams</arm_group_label>
    <other_name>Mexitil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or
             definite ALS as defined by revised El Escorial criteria.

          2. Age 18 years or older.

          3. Symptom onset of weakness or spasticity due to ALS ≤ 60 months prior to Screening
             Visit.

          4. Slow vital capacity (SVC) measure ≥50% of predicted for gender, height, and age at the
             screening visit.

          5. Must be able to swallow capsules throughout the course of the study, according to Site
             Investigator judgment.

          6. Capable of providing informed consent and following trial procedures.

          7. For TMS: a resting motor threshold defined as 50% of pulses eliciting a motor evoked
             potential (MEP) of amplitude ≥ 50 µV.

          8. For TTNCS: median Compound Muscle Action Potential (CMAP) ≥ 1.5 mV.

          9. Subjects must not have taken riluzole for at least 30 days or be on a stable dose of
             riluzole for at least 30 days prior to the Screening Visit and continue on the stable
             dose throughout the course of the study (riluzole-naïve subjects are permitted in the
             study).

         10. Subjects must not have taken medication for muscle cramping such as cyclobenzaprine,
             baclofen, carisoprodol, or methocarbamol, for at least 30 days prior to screening or
             be on a stable dose for at least 60 days prior to screening.

         11. Geographic accessibility to the site.

         12. Women must not become pregnant for the duration of the study and must be willing to
             use two contraceptive therapies and have a negative pregnancy test throughout the
             course of the study.

         13. Use of medications known to affect the neurophysiology measures in the study must be
             scheduled, not as needed (pro re nata, PRN). A subject must have been on a fixed dose
             for 30 days prior to the Screening Visit, and there must be no reason to believe that
             a subsequent change would be necessary during the course of the study. These
             medications include: benzodiazepines, muscle relaxants, tricyclic antidepressants,
             selective serotonin reuptake inhibitors, non-selective serotonin reuptake inhibitors,
             hypnotics (including anti-histamines) and anti-cholinergics.

        Exclusion Criteria:

          1. Invasive ventilator dependence, such as tracheostomy.

          2. Creatinine level greater than 1.5 mg/dL at screening.

          3. Serum Glutamic-Oxaloacetic (SGOT/AST) / Serum Glutamic-Pyruvic (SGPT/ALT) greater than
             3 times the upper limit of normal at screening.

          4. History of known sensitivity or intolerability to mexiletine or lidocaine.

          5. Any history of either substance abuse within the past year, unstable psychiatric
             disease, cognitive impairment, or dementia.

          6. Clinically significant conduction abnormalities on electrocardiogram or a known
             history of cardiac arrhythmia.

          7. Known history of epilepsy.

          8. Known history of congestive heart failure (CHF) or history of myocardial infarction
             within the past 24 months.

          9. Use of mexiletine for 30 days prior to Screening Visit.

         10. Exposure to any other experimental agent (off-label use or investigational) including
             high dose creatine (&gt;10 grams a day) within 30 days prior to Screening Visit.

         11. Metal in the head and neck region, cardiac pacemaker or brain stimulator, cochlear
             implants, implanted infusion device or personal history of epilepsy.

         12. Use of amiodarone, flecainide, duloxetine, tizanidine, or clozapine.

         13. Pregnant women or women currently breastfeeding.

         14. Placement of Diaphragm Pacing System (DPS) device &lt; 60 days prior to Screening Visit.

         15. Planned DPS device implantation during study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Universtiy Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alsconsortium.org/</url>
    <description>Northeast ALS Consortium Website</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <results_first_submitted>October 6, 2019</results_first_submitted>
  <results_first_submitted_qc>November 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2019</results_first_posted>
  <last_update_submitted>November 17, 2019</last_update_submitted>
  <last_update_submitted_qc>November 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Michael D Weiss</investigator_full_name>
    <investigator_title>Professor, Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>SALS</keyword>
  <keyword>Mexiletine</keyword>
  <keyword>TMS</keyword>
  <keyword>NCS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mexiletine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02781454/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02781454/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 9 Northeast ALS Consortium (NEALS) centers in the US. These NEALS centers were academic clinical research centers with established practices where sporadic ALS (sALS) patients are regularly seen and treated.</recruitment_details>
      <pre_assignment_details>Within 21 days prior to treatment assignment, patients were screened for eligibility based on inclusion/exclusion criteria. Failure to meet any of these criteria at the time of this screening would result in exclusion from the study, and these patients would not be assigned to a treatment group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mexiletine, 300 Milligrams</title>
          <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
        </group>
        <group group_id="P2">
          <title>Mexiletine, 600 Milligrams</title>
          <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mexiletine, 300 Milligrams</title>
          <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
        </group>
        <group group_id="B2">
          <title>Mexiletine, 600 Milligrams</title>
          <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="10.8"/>
                    <measurement group_id="B2" value="60.5" spread="14.1"/>
                    <measurement group_id="B3" value="52.0" spread="11.3"/>
                    <measurement group_id="B4" value="57.2" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>El Escorial Diagnosis</title>
          <description>Participants were classified according to the El Escorial World Federation of Neurology Criteria for the Diagnosis of ALS (Brooks J Neurol Sci 1994) based on the extent of ALS disease signs and symptoms consistent with neurodegeneration of upper and lower motor neurons</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Possible</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prob Lab Supported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Probable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Definite</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Resting Motor Threshold</title>
        <description>The resting motor threshold (RMT) assessed from single pulse transcranial magnetic stimulation (TMS) measurements made before treatment, after 4 weeks of treatment, and then again after a 4 week washout, was used as the primary pharmacodynamic marker of cortical hyperexcitability. RMT is the stimulus intensity required to produce and maintain a 0.2 mV peak-to-peak motor evoked potential of the abductor pollicis brevis muscle by TMS. A smaller RMT is thought to suggest greater neuronal excitability.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 and from Week 4 to Week 8 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Resting Motor Threshold</title>
          <description>The resting motor threshold (RMT) assessed from single pulse transcranial magnetic stimulation (TMS) measurements made before treatment, after 4 weeks of treatment, and then again after a 4 week washout, was used as the primary pharmacodynamic marker of cortical hyperexcitability. RMT is the stimulus intensity required to produce and maintain a 0.2 mV peak-to-peak motor evoked potential of the abductor pollicis brevis muscle by TMS. A smaller RMT is thought to suggest greater neuronal excitability.</description>
          <units>percentage of maximum stimulus output</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.430" spread="2.323"/>
                    <measurement group_id="O2" value="0.805" spread="2.207"/>
                    <measurement group_id="O3" value="4.746" spread="2.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from week 4 to week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.465" spread="2.357"/>
                    <measurement group_id="O2" value="-0.284" spread="2.169"/>
                    <measurement group_id="O3" value="-2.908" spread="2.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo for change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>-5.558</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.80</ci_lower_limit>
            <ci_upper_limit>-0.315</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Short-interval Intracortical Inhibition</title>
        <description>Short-interval intracortical inhibition (SICI) is a measure of neuronal excitability measured by dual pulse TMS with a conditioned (80% of RMT) and test pulses (120% of RMT) to generate a stable MEP amplitude of 0.2 mV, averaged over interstimulus intervals of 1-7 ms. It is thought to reflect refractory cortical axons and subsequent resynchronization of cortico-cortical and corticomotoneuronal volleys or activation of non-GABAergic cortical inhibitory circuits (initial phase) and synaptic neurotransmission through GABAA receptors (second phase). The value for SICI thought to be maximally sensitive for detecting in changes in ALS subjects compared to controls is is derived by measuring the motor evoked potential amplitude (MEP) at an interstimulus interval of 3 ms (ISI 3 ms) and normalizing to the MEP amplitude at 120% of the resting motor threshold (MEP 120% RMT). A reduction in SICI reflecting greater excitability would generate a larger ratio of MEP ISI 3 ms/MEP 120% RMT.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Short-interval Intracortical Inhibition</title>
          <description>Short-interval intracortical inhibition (SICI) is a measure of neuronal excitability measured by dual pulse TMS with a conditioned (80% of RMT) and test pulses (120% of RMT) to generate a stable MEP amplitude of 0.2 mV, averaged over interstimulus intervals of 1-7 ms. It is thought to reflect refractory cortical axons and subsequent resynchronization of cortico-cortical and corticomotoneuronal volleys or activation of non-GABAergic cortical inhibitory circuits (initial phase) and synaptic neurotransmission through GABAA receptors (second phase). The value for SICI thought to be maximally sensitive for detecting in changes in ALS subjects compared to controls is is derived by measuring the motor evoked potential amplitude (MEP) at an interstimulus interval of 3 ms (ISI 3 ms) and normalizing to the MEP amplitude at 120% of the resting motor threshold (MEP 120% RMT). A reduction in SICI reflecting greater excitability would generate a larger ratio of MEP ISI 3 ms/MEP 120% RMT.</description>
          <units>unitless ratio MEP ISI 3 ms/MEP 120% RMT</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.655" lower_limit="0.437" upper_limit="0.983"/>
                    <measurement group_id="O2" value="0.886" lower_limit="0.608" upper_limit="1.291"/>
                    <measurement group_id="O3" value="0.961" lower_limit="0.634" upper_limit="1.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo ratio of week 4 to week 0</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.332</p_value>
            <p_value_desc>linear contrast active vs placebo</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>0.792</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.484</ci_lower_limit>
            <ci_upper_limit>1.296</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Motor Evoked Potential Amplitude</title>
        <description>The motor evoked potential (MEP) amplitude is taken from single pulse transcranial magnetic stimulation (TMS) and reflects the density of corticomotoneuronal projections onto motor neurons and is affected by cortical hyperexcitability early in ALS where it is thought to be larger than age-matched controls and axonal degeneration later in the disease when it decreases in amplitude. The MEP is most reliable in assessing cortical motor neuronal preservation and excitability when normalized to the peak compound nerve action potential (CMAP) amplitude which reflects the integrity of peripheral motor nerve axons. It is also normalized here to 120% of the RMT to derive a ratio of MEP at 120% RMT/peak CMAP.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <population>MEP at 120% RMT/peak CMAP</population>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Motor Evoked Potential Amplitude</title>
          <description>The motor evoked potential (MEP) amplitude is taken from single pulse transcranial magnetic stimulation (TMS) and reflects the density of corticomotoneuronal projections onto motor neurons and is affected by cortical hyperexcitability early in ALS where it is thought to be larger than age-matched controls and axonal degeneration later in the disease when it decreases in amplitude. The MEP is most reliable in assessing cortical motor neuronal preservation and excitability when normalized to the peak compound nerve action potential (CMAP) amplitude which reflects the integrity of peripheral motor nerve axons. It is also normalized here to 120% of the RMT to derive a ratio of MEP at 120% RMT/peak CMAP.</description>
          <population>MEP at 120% RMT/peak CMAP</population>
          <units>unitless ratio of ms/ms</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.589" lower_limit="0.315" upper_limit="1.102"/>
                    <measurement group_id="O2" value="0.490" lower_limit="0.249" upper_limit="0.965"/>
                    <measurement group_id="O3" value="1.308" lower_limit="0.695" upper_limit="2.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo ratio of week 4 to week 0</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>0.411</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.208</ci_lower_limit>
            <ci_upper_limit>0.810</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Cortical Silent Period</title>
        <description>The cortical silent period (CSP) is recorded with single pulse TMS as a duration from the onset of the MEP response to resumption of voluntary electromyography activity with the patient performing a voluntary contraction, set to 30% of maximal voluntary contraction. A shorter CSP compared to controls would reflect greater excitability.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Cortical Silent Period</title>
          <description>The cortical silent period (CSP) is recorded with single pulse TMS as a duration from the onset of the MEP response to resumption of voluntary electromyography activity with the patient performing a voluntary contraction, set to 30% of maximal voluntary contraction. A shorter CSP compared to controls would reflect greater excitability.</description>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.937" lower_limit="-31.75" upper_limit="39.624"/>
                    <measurement group_id="O2" value="4.823" lower_limit="-29.76" upper_limit="39.408"/>
                    <measurement group_id="O3" value="4.037" lower_limit="-30.84" upper_limit="38.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo for change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.986</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>0.343</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.36</ci_lower_limit>
            <ci_upper_limit>42.042</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Strength Duration Time Constant</title>
        <description>The strength duration time constant (SDTC) is used in threshold tracking nerve axonal excitability studies and is interpreted as a measure of axonal excitability that is dependent upon the biophysical properties of the axonal membrane at the node of Ranvier, especially persistent sodium current. It is derived from the relationship between stimulus duration and intensity. A higher SDTC would reflect greater excitability of motor nerve axons.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <population>strength duration time constant</population>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Strength Duration Time Constant</title>
          <description>The strength duration time constant (SDTC) is used in threshold tracking nerve axonal excitability studies and is interpreted as a measure of axonal excitability that is dependent upon the biophysical properties of the axonal membrane at the node of Ranvier, especially persistent sodium current. It is derived from the relationship between stimulus duration and intensity. A higher SDTC would reflect greater excitability of motor nerve axons.</description>
          <population>strength duration time constant</population>
          <units>milliseconds</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.895" lower_limit="0.802" upper_limit="0.998"/>
                    <measurement group_id="O2" value="0.966" lower_limit="0.848" upper_limit="1.099"/>
                    <measurement group_id="O3" value="0.935" lower_limit="0.837" upper_limit="1.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo ratio of week 4 to week 0</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.915</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>0.994</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.876</ci_lower_limit>
            <ci_upper_limit>1.126</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Depolarizing Threshold Electrotonus (90-100 ms)</title>
        <description>Depolarizing threshold electrotonus (90-100 ms) (TEd 90-100 ms) is used in threshold tracking nerve axonal excitability studies in which long-lasting subthreshold depolarizing currents are generated, measured at 90-100 ms following the stimulus. This measure is associated with a decrease in the membrane excitability threshold due to opening of potassium channels on the axonal membrane. Intrinsic changes in axonal excitability properties, such as thought to occur in ALS, could possibly alter this measure, presumably by decreasing TEd 90-100 ms more substantially than normal.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Depolarizing Threshold Electrotonus (90-100 ms)</title>
          <description>Depolarizing threshold electrotonus (90-100 ms) (TEd 90-100 ms) is used in threshold tracking nerve axonal excitability studies in which long-lasting subthreshold depolarizing currents are generated, measured at 90-100 ms following the stimulus. This measure is associated with a decrease in the membrane excitability threshold due to opening of potassium channels on the axonal membrane. Intrinsic changes in axonal excitability properties, such as thought to occur in ALS, could possibly alter this measure, presumably by decreasing TEd 90-100 ms more substantially than normal.</description>
          <units>percentage of threshold depolarization</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.140" lower_limit="-4.925" upper_limit="4.645"/>
                    <measurement group_id="O2" value="4.005" lower_limit="-1.375" upper_limit="9.384"/>
                    <measurement group_id="O3" value="0.844" lower_limit="-3.735" upper_limit="5.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo for change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.694</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>1.089</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.609</ci_lower_limit>
            <ci_upper_limit>6.786</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Hyperpolarizing Threshold Electrotonus (90-100 ms)</title>
        <description>Hyperpolarizing threshold electrotonus (90-100 ms) (TEh 90-100 ms) is used in threshold tracking nerve axonal excitability studies in which long-lasting subthreshold hyperpolarizing currents are generated, measured at 90-100 ms following the stimulus. This measure is associated with an increase in the membrane excitability threshold due to closure of potassium channels causing increased resistance of the internodal axonal membrane. Intrinsic changes in axonal excitability properties, such as thought to occur in ALS, could possibly alter this measure.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Hyperpolarizing Threshold Electrotonus (90-100 ms)</title>
          <description>Hyperpolarizing threshold electrotonus (90-100 ms) (TEh 90-100 ms) is used in threshold tracking nerve axonal excitability studies in which long-lasting subthreshold hyperpolarizing currents are generated, measured at 90-100 ms following the stimulus. This measure is associated with an increase in the membrane excitability threshold due to closure of potassium channels causing increased resistance of the internodal axonal membrane. Intrinsic changes in axonal excitability properties, such as thought to occur in ALS, could possibly alter this measure.</description>
          <units>percentage threshold hyperpolarization</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.184" lower_limit="-21.57" upper_limit="1.204"/>
                    <measurement group_id="O2" value="2.230" lower_limit="-10.52" upper_limit="14.979"/>
                    <measurement group_id="O3" value="-4.219" lower_limit="-15.00" upper_limit="6.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo for change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.969</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>0.242</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.64</ci_lower_limit>
            <ci_upper_limit>13.126</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Superexcitability</title>
        <description>Superexcitability is a component of recovery cycle analysis assessing motor axonal excitability, employing threshold tracking nerve conduction study. It is a depolarizing afterpotential measured following a single supramaximal stimulus followed by a second smaller stimulus of variable intensity and reflects passive depolarization of the internodal axon.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Superexcitability</title>
          <description>Superexcitability is a component of recovery cycle analysis assessing motor axonal excitability, employing threshold tracking nerve conduction study. It is a depolarizing afterpotential measured following a single supramaximal stimulus followed by a second smaller stimulus of variable intensity and reflects passive depolarization of the internodal axon.</description>
          <units>percentage of threshold change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.234" lower_limit="-2.129" upper_limit="6.597"/>
                    <measurement group_id="O2" value="1.511" lower_limit="-3.391" upper_limit="6.413"/>
                    <measurement group_id="O3" value="-0.724" lower_limit="-4.974" upper_limit="3.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo for change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.323</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>2.597</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.772</ci_lower_limit>
            <ci_upper_limit>7.966</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Subexcitability</title>
        <description>Subexcitability is a component of recovery cycle analysis assessing motor axonal excitability, employing threshold tracking nerve conduction study. It is a late hyperpolarizing after potential measured following a single supramaximal stimulus followed by a second smaller stimulus of variable intensity and is related to the very slow turn-off of slow potassium channels.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Subexcitability</title>
          <description>Subexcitability is a component of recovery cycle analysis assessing motor axonal excitability, employing threshold tracking nerve conduction study. It is a late hyperpolarizing after potential measured following a single supramaximal stimulus followed by a second smaller stimulus of variable intensity and is related to the very slow turn-off of slow potassium channels.</description>
          <units>percentage of threshold change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.563" lower_limit="-5.706" upper_limit="0.581"/>
                    <measurement group_id="O2" value="-0.575" lower_limit="-4.178" upper_limit="3.027"/>
                    <measurement group_id="O3" value="0.448" lower_limit="-3.001" upper_limit="3.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo for change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.273</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>-2.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.767</ci_lower_limit>
            <ci_upper_limit>1.733</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Frequency of Muscle Cramps</title>
        <description>Will be assessed using a daily muscle cramps diary tabulated weekly beginning at Baseline.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; comparisons of treatments at Weeks 3-4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Frequency of Muscle Cramps</title>
          <description>Will be assessed using a daily muscle cramps diary tabulated weekly beginning at Baseline.</description>
          <units>muscle cramps/week</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.430" lower_limit="1.152" upper_limit="10.210"/>
                    <measurement group_id="O2" value="1.987" lower_limit="0.686" upper_limit="5.755"/>
                    <measurement group_id="O3" value="3.774" lower_limit="0.687" upper_limit="20.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.713</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>0.708</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.111</ci_lower_limit>
            <ci_upper_limit>4.535</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Frequency of Fasciculations (Muscle Twitching)</title>
        <description>Will be assessed using a daily fasciculations diary tabulated as a percentage of days from weeks 3-4.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; comparisons of treatments at Weeks 3-4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Frequency of Fasciculations (Muscle Twitching)</title>
          <description>Will be assessed using a daily fasciculations diary tabulated as a percentage of days from weeks 3-4.</description>
          <units>percentage of days with fasciculations</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised</title>
        <description>The Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) is an instrument for evaluating the functional status of patients with ALS that includes functions related to speech, swallowing, salivation, fine motor control, gross motor function, and respiration. The score is the sum of 12 items (range 0 to 48) with higher scores reflecting better function.</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised</title>
          <description>The Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) is an instrument for evaluating the functional status of patients with ALS that includes functions related to speech, swallowing, salivation, fine motor control, gross motor function, and respiration. The score is the sum of 12 items (range 0 to 48) with higher scores reflecting better function.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.414" lower_limit="-2.554" upper_limit="-0.274"/>
                    <measurement group_id="O2" value="-1.038" lower_limit="-2.352" upper_limit="0.276"/>
                    <measurement group_id="O3" value="-0.827" lower_limit="-2.141" upper_limit="0.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo for change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.601</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>-0.399</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.966</ci_lower_limit>
            <ci_upper_limit>1.169</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Slow Vital Capacity</title>
        <description>Measure of decline in respiratory muscle strength</description>
        <time_frame>Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine, 300 Milligrams</title>
            <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O2">
            <title>Mexiletine, 600 Milligrams</title>
            <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Slow Vital Capacity</title>
          <description>Measure of decline in respiratory muscle strength</description>
          <units>maximum percent predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.532" lower_limit="-4.425" upper_limit="3.361"/>
                    <measurement group_id="O2" value="-6.918" lower_limit="-11.370" upper_limit="-2.461"/>
                    <measurement group_id="O3" value="-0.991" lower_limit="-5.450" upper_limit="3.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of active (300 and 600 mg) vs placebo for change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.285</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>linear contrast active vs placebo</param_type>
            <param_value>-2.734</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.938</ci_lower_limit>
            <ci_upper_limit>2.471</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mexiletine, 300 Milligrams</title>
          <description>Mexiletine, 300 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
        </group>
        <group group_id="E2">
          <title>Mexiletine, 600 Milligrams</title>
          <description>Mexiletine, 600 milligrams by mouth per day for 4 weeks.
Mexiletine</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo, by mouth per day for 4 weeks.
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear signs and symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental pain and sensation disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea (excl infective)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspeptic signs and symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal atonic and hypomotility disorders NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral dryness and saliva altered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral soft tissue pain and paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Implant and catheter site reactions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Asthenic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract and lung infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Non-site specific injuries NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pains</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle related signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neurological signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Speech and language abnormalities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tremor (excl congenital)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbances in initiating and maintaining sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder and urethral symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Breathing abnormalities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract signs and symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythemas</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="8" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rashes, eruptions and exanthems NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral embolism and thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael D. Weiss</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-598-7688</phone>
      <email>mdweiss@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

